Search research articles
Contact Us
Filters
Showing results (361-370 of 512) with videos related to
Page
of 52
Sort By:
The European Respiratory Journal
|
August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Pascale Tomasini, Solenn Brosseau, Julien Mazières, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2025
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
Arianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Molecular Cancer
|
November 4, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 18, 2019
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression
Mihaela Aldea, Lizza Hendriks, Laura Mezquita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 5, 2017
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Clémence Basse, Sébastien Thureau, Suzanna Bota, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
Diego Enrico, Ludovic Lacroix, Jeanne Chen, et al.
The Lancet. Oncology
|
September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
Jordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Page
of 52
Search research articles
Search
Showing results (361-370 of 512) with videos related to
Sort By:
Page
of 52
The European Respiratory Journal
|
August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Pascale Tomasini, Solenn Brosseau, Julien Mazières, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2025
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
Arianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
Molecular Cancer
|
November 4, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 18, 2019
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression
Mihaela Aldea, Lizza Hendriks, Laura Mezquita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 5, 2017
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Clémence Basse, Sébastien Thureau, Suzanna Bota, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
Diego Enrico, Ludovic Lacroix, Jeanne Chen, et al.
The Lancet. Oncology
|
September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
Jordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Page
of 52